Use of pharmacokinetic-pharmaco dynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development. Simulation results predict that 500 mg of doripenem administered over 1 h every 8 h would be effective against bacterial strains with MICs less than 2 mu g/ml and that less susceptible strains could be treated with prolonged infusions.